The rEVO Biologics pipeline is focused on meeting the needs of under-served patient populations through innovative recombinant protein therapies. 

Today we’re already making a real difference in hematology with the market success of our lead product, ATryn® Antithrombin (Recombinant). We are also actively evaluating additional applications for ATryn.